Cargando…
Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
Although the probability of both parents being affected by BRCA1 mutations is not negligible, such families have not been systematically described in the literature. Here we present a large breast-ovarian cancer family, where 3 sisters and 1 half-sister inherited maternal BRCA1 5382insC mutation whi...
Autores principales: | Sokolenko, Anna P, Voskresenskiy, Dmitry A, Iyevleva, Aglaya G, Bit-Sava, Elena M, Gutkina, Nadezhda I, Anisimenko, Maxim S, Yu Sherina, Nathalia, Mitiushkina, Nathalia V, Ulibina, Yulia M, Yatsuk, Olga S, Zaitseva, Olga A, Suspitsin, Evgeny N, Togo, Alexandr V, Pospelov, Valery A, Kovalenko, Sergey P, Semiglazov, Vladimir F, Imyanitov, Evgeny N |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653717/ https://www.ncbi.nlm.nih.gov/pubmed/19338681 http://dx.doi.org/10.1186/1897-4287-7-2 |
Ejemplares similares
-
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
por: Suspitsin, Evgeny N, et al.
Publicado: (2009) -
Hereditary cancer syndromes
por: Imyanitov, Evgeny N, et al.
Publicado: (2023) -
Comprehensive evaluation of the test for 5′‐/3′‐end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer
por: Mitiushkina, Natalia V., et al.
Publicado: (2022) -
BRCA1 4153delA founder mutation in Russian ovarian cancer patients
por: Krylova, Nadezhda Yu, et al.
Publicado: (2006) -
Cytotoxic and targeted therapy for hereditary cancers
por: Iyevleva, Aglaya G., et al.
Publicado: (2016)